Effects of pituitary adenylate cyclase activating polypeptide in a rat model of traumatic brain injury

Regulatory Peptides

Volumn 123, Issue 1-3 SPEC. ISS., 2004, Pages 69-75

  Farkas, Orsolya ^a   Tamás, Andrea ^a   Zsombok, Andrea ^a   Reglodi, Dóra ^a   Pál, József ^a   Büki, Andras ^a   Lengvári, István ^a   Povlishock, John T ^b   Dóczi, Tamás ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Beta amyloid precursor protein; Corticospinal tract; Neuroprotection; Traumatic axonal injury; Traumatic brain injury

Indexed keywords

AMYLOID BETA PROTEIN; ANTISERUM; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; PROTEIN PRECURSOR;

ACCELERATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INJURY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIFFUSE AXONAL INJURY; DRUG EFFECT; EXPERIMENTAL MODEL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; NERVE FIBER TRANSPORT; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PYRAMIDAL TRACT; RAT;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; AXONAL TRANSPORT; AXONS; BRAIN INJURIES; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAVENTRICULAR; NERVE GROWTH FACTORS; NEUROPEPTIDES; NEUROPROTECTIVE AGENTS; NEUROTRANSMITTER AGENTS; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RATS; RATS, WISTAR;

ANIMALIA;

EID: 7044245785     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2004.05.014     Document Type: Article

References (51)

1. Miyata A., Arimura A., Dahl R.R., Minamino N., Uehara A., Jiang L., et al. Isolation of a novel 38-residue hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem. Biophys. Res. Commun. 164:1989;567-574
2. Arimura A. Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems. Jpn. J. Physiol. 48:1998;301-331
3. Vaudry D., Gonzalez B.J., Basille M., Yon L., Fournier A., Vaudry H. Pituitary adenylate cyclase activating polypeptide and its receptors: from structure to functions. Pharmacol. Rev. 52:2000;269-324
4. Arimura A., Somogyvari-Vigh A., Weill C., Fiore R.C., Tatsuno I., Bay V., et al. PACAP functions as a neurotrophic factor. Ann. N. Y. Acad. Sci. U. S. A. 739:1994;228-243
5. Frechilla D., Garcia-Osta A., Palacios S., Cenarruzabeitia E., Del Rio J. BDNF mediates the neuroprotective effect of PACAP-38 on rat cortical neurons. NeuroReport. 12:2001;919-923
6. Morio H., Tatsuno I., Hirai A., Tamura Y., Saito Y. Pituitary adenylate cyclase activating polypeptide protects rat-cultured cortical neurons from glutamate-induced cytotoxicity. Brain Res. 741:1996;82-88
7. Onoue S., Endo K., Ohshima K., Yajima T., Kashimoto K. The neuropeptide PACAP attenuates β-amyloid (1-42)-induced toxicity in PC12 cells. Peptides. 23:2002;1471-1478
8. Shoge K., Mishima H.K., Saitoh T., Ishihara K., Tamura Y., Shiomi H., et al. Attenuation by PACAP of glutamate-induced neurotoxicity in cultured retinal neurons. Brain Res. 839:1999;66-73
9. Kong L.Y., Maderdrut J.L., Jeohn G.H., Hong J.S. Reduction of lipopolysaccharide-induced neurotoxicity in mixed cortical neuron/glia cultures by femtomolar concentrations of pituitary adenylate cyclase activating polypeptide. Neuroscience. 91:1999;493-500
10. Vaudry D., Pamantung T.F., Basille M., Rouselle C., Fournier A., Vaudry H., et al. PACAP protects cerebellar granule neurons against oxidative stress-induced apoptosis. Eur. J. Neurosci. 15:2002;1451-1460
11. Katahira M., Yone K., Arishima Y., Nagamine T., Komiya S., Iwata S., et al. The neuroprotective effects of PACAP on spinal cord injury (SCI) in rats. Regul. Pept. 115:2003;49. [abstract]
12. Kimura H., Kawatani M., Ito E., Ishikawa K. Effects of pituitary adenylate cyclase activating polypeptide on facial nerve recovery in the guinea pig. Laryngoscope. 113:2003;1000-1006
13. Seki T., Izumi S., Shioda S., Arimura A. Pituitary adenylate cyclase activating polypeptide (PACAP) protects ganglion cell death against cutting of optic nerve in the rat retina. Regul. Pept. 115:2003;55. [abstract]
14. Reglodi D., Lubics A., Tamás A., Szalontay L., Lengvári I. Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson's disease. Behav. Brain Res. 151:2004;303-312
15. Uchida D., Arimura A., Somogyvári-Vigh A., Shioda S., Banks W. Prevention of ischemia-induced death of hippocampal neurons by pituitary adenylate-cyclase activating polypeptide. Brain Res. 736:1996;280-286
16. Reglodi D., Somogyvári-Vigh A., Vigh S., Kozicz T., Arimura A. Delayed systemic administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat. Stroke. 31:2000;1411-1417
17. Ohtaki H., Dohi K., Yin T., Takaki A., Nakajo S., Shioda S. Neuroprotective effect of PACAP38 through IL-6 after focal ischemia in mouse. Regul. Pept. 115:2003;53. [abstract]
18. Leker R.R., Shohami E. Cerebral ischemia and trauma - different etiologies yet similar mechanisms: neuroprotective opportunities. Brain Res. Rev. 39:2002;55-73
19. Povlishok J.T. Traumatically induced axonal injury: pathogenesis and pathobiological implications. Brain Pathol. 2:1992;1-12
20. Maxwell W.L., Povlishok J.T., Graham D.L. A mechanistic analysis of nondisruptive axonal injury: a review. J. Neurotrauma. 14:1997;419-440
21. Büki A., Okonkwo D.O., Wang K.K., Povlishok J.T. Cytochrome c release and caspase activation in traumatic axonal injury. J. Neurosci. 20:2000;2825-2834
22. Marmarou A., Foda M.A.A.-E, Van Den Brink W., Campbell J., Kita H., Demetriadou K. A new model of diffuse brain injury in rats: Part I. Pathophysiology and biomechanics. J. Neurosurg. 80:1994;291-300
23. Foda M.A., Marmarou A. A new model of diffuse brain injury in rats: Part II. Morphological characterization. J. Neurosurg. 80:1994;301-313
24. Zamboni L., Martino L. Buffered picric acid-formaldehyde: a new rapid fixative for electron microscopy. J. Cell Biol. 35:1967;148A
25. Povlishok J.T., Marmarou A., McIntosh T., Trojanowski J.Q., Moroi J. Impact acceleration injury in the rat: evidence for focal axolemmal change and related neurofilament sidearm alteration. J. Neuropathol. Exp. Neurol. 56:1997;347-359
26. Stone J.R., Singleton R.H., Povlishok J.T. Antibodies to the C-terminus of the beta-amyloid precursor protein (APP): a site specific marker for the detection of traumatic axonal injury. Brain Res. 871:2000;288-302
27. Gentleman S.M., Nash M.J., Sweeting C.J., Graham D.I., Roberts G.W. Beta-amyloid precursor protein (beta-APP) as a marker for axonal injury after head injury. Neurosci. Lett. 160:1993;139-144
28. Stone J.R., Walker S.A., Povlishok J.T. The visualisation of a new class of traumatically injured axons through the use of a modified method of microwave antigen retrieval. Acta Neuropathol. 97:1999;335-345
29. Büki A., Okonkwo D.O., Povlishok J.T. Postinjury cyclosporin A administration limits axonal damage and disconnection in traumatic brain injury. J. Neurotrauma. 16:1999;511-521
30. Gozes I. Neuroprotective drug delivery and development: potential new therapeutics. Trends Neurosci. 24:2001;700-705
31. Gozes I., Perl O., Giladi E., Davidson A., Ashur-Fabian O., Rubinraut S., et al. Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: neuroprotective drug design. Proc. Natl. Acad. Sci. U. S. A. 96:1999;4143-4148
32. Dibbern D.A., Glazner G.W., Gozes I., Brenneman D.E., Hill J.M. Inhibition of murine embryonic growth by human immunodeficiency virus envelope protein and its prevention by vasoactive intestinal peptide and activity-dependent neurotrophic factor. J. Clin. Invest. 99:1997;2837-2841
33. Gozes I., Divinsky I., Pilzer I., Fridkin M., Brenneman D.E., Spier A.D. From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division. J. Mol. Neurosci. 20:2003;315-322
34. Deutsch P.J., Sun Y. The 38-amino acid form of pituitary adenylate cyclase activating polypeptide stimulates dual signaling cascades in PC12 cells and promotes neurite outgrowth. J. Biol. Chem. 267:1992;5108-5113
35. Waschek J.A. Multiple actions of pituitary adenylate cyclase activating peptide in nervous system development and regeneration. Dev. Neurosci. 24:2002;14-23
36. Kim W.K., Kan Y., Ganea D., Hart R.P., Gozes I., Jonakait M. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit tumor necrosis factor-α production in injured spinal cord and in activated microglia via cAMP-dependent pathway. J. Neurosci. 20:2000;3622-3630
37. Skoglosa Y., Lewen A., Takei N., Hillered L., Lindholm D. Regulation of pituitary adenylate cyclase activating polypeptide and its receptor type 1 after traumatic brain injury: comparison with brain-derived neurotrophic factor and the induction of neuronal cell death. Neuroscience. 90:1999;235-247
38. Shioda S., Ozawa H., Dohi K., Mizushima H., Matsumoto K., Nakajo S., et al. PACAP protects hippocampal neurons against apoptosis: involvement of JNK/SAPK signaling pathway. Ann. N. Y. Acad. Sci. 865:1998;111-117
39. Vaudry D., Gonzalez B.J., Basille M., Pamantung T.F., Fontaine M., Fournier A., et al. The neuroprotective effect of pituitary adenylate cyclase activating polypeptide on cerebellar granule cells is mediated through inhibition of the CED3-related cystein protease caspase-3/CPP32. Proc. Natl. Acad. Sci. U. S. A. 97:2000;13390-13395
40. Vaudry D., Rouselle C., Basille M., Falluel-Morel A., Pamantung T.F., Fontaine M., et al. Pituitary adenylate cyclase activating polypeptide protects rat cerebellar granule neurons against ethanol-induced apoptotic cell death. Proc. Natl. Acad. Sci. U. S. A. 99:2002;6398-6403
41. Delgado M., Leceta J., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit the production of inflammatory mediators by activated microglia. J. Leukoc. Biol. 73:2003;155-164
42. Pettus E.H., Christman C.W., Giebel M.L., Povlishok J.T. Traumatically induced altered membrane permeability: its relationship to traumatically induced reactive axonal change. J. Neurotrauma. 11:1994;507-522
43. Tabuchi A., Funaji K., Nakatsubo J., Fukuchi M., Tsuchiya T., Tsuda M. Inactivation of aconitase during apoptosis of mouse cerebellar granule neurons induced by a deprivation of membrane depolarization. J. Neurosci. Res. 71:2003;504-515
44. Okonkwo D.O., Buki A., Siman R., Povlishock J.T. Cyclosporin A limits calcium-induced axonal damage following traumatic brain injury. NeuroReport. 10:1999;353-358
45. Banks W.A., Kastin A.J., Komaki G., Arimura A. Passage of pituitary adenylate cyclase activating polypeptide 1-27 and pituitary adenylate cyclase activating polypeptide 1-38 across the blood-brain barrier. J. Pharmacol. Exp. Ther. 267:1993;690-696
46. Somogyvári-Vigh A., Pan W., Reglodi D., Vigh S., Kastin A.J., Arimura A. The passage of pituitary adenylate cyclase activating polypeptide across the blood-brain barrier during focal cerebral ischemia. Regul. Pept. 91:2000;89-95
47. Nonaka N., Banks W.A., Mizushima H., Shioda S., Morley J.E. Regional differences in PACAP transport across the blood-brain barrier in mice: a possible influence of strain, amyloid β protein and age. Peptides. 23:2002;2197-2202
48. Somogyvári-Vigh A., Svoboda-Teet J., Vigh S., Arimura A. Is an intravenous bolus injection required prior to initiating slow intravenous infusion of PACAP38 for prevention of neuronal death induced by global ischemia? The possible presence of a binding protein for PACAP38 in blood. Ann. N. Y. Acad. Sci. 865:1998;595-600
49. Tams J.W., Johnsen A.H., Fahrenkrug J. Identification of pituitary adenylate cyclase activating polypeptide 1-38-binding factor in human plasma, as ceruloplasmin. Biochem. J. 341:1999;271-276
50. Arimura A. Perspectives on the development of a neuroprotective drug based on PACAP. Regul. Pept. 115:2003;40. [abstract]
51. Zhou C.J., Shioda S., Yada T., Inagaki N., Pleasure S.J., Kikuyama S. PACAP and its receptors exert pleiotropic effects in the nervous system by activating multiple signaling pathways. Curr. Prot. Pept. Sci. 3:2002;423-439